SCHEMBL5135032

SCHEMBL5135032

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1c(Cl)cccc1Cl)CC1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
TSHR P16473 5/20 0.37
ALDH1A1 P00352 6/20 0.36
KDM4E B2RXH2 5/20 0.36
HSD17B10 Q99714 5/20 0.36
HPGD P15428 5/20 0.36
CYP3A4 P08684 4/20 0.36
CRHR1 P34998 5/20 0.34
HDAC1 Q13547 1/20 0.34
ADORA3 P0DMS8 2/20 0.34
ADORA2A P29274 2/20 0.34
ADORA2B P29275 2/20 0.34
ADORA1 P30542 2/20 0.34
ALOX15 P16050 1/20 0.34
CCR4 P51679 1/20 0.33
MAPK1 P28482 1/20 0.33
P2RX7 Q99572 1/20 0.33
LMNA P02545 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ABCC1 P33527 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134976 0.94 C5AR1 (0.37) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL5135152 0.91 C5AR1 (0.41) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL5137537 0.91 C5AR1 (0.34) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL5135866 0.91 C5AR1 (0.39) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL651501 0.90 C5AR1 (0.44) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL5135466 0.89 C5AR1 (0.39) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL5137864 0.88 C5AR1 (0.44) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL5135678 0.88 C5AR1 (0.43) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL5136646 0.87 C5AR1 (0.45) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL648237 0.87 TSHR (0.42) C5AR1TSHRALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed